Skip to main content

Table 2 Changes in MRI parameters

From: Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study

mITT-LOCF population

24 months

   

Chondroitin sulfate

Celecoxib

p valuea

   

(n = 69)

(n = 69)

   

Cartilage volume loss (%)

Lateral compartment

–4.1 ± 3.1

–4.4 ± 3.0

0.814

   

 Condyle

–3.0 ± 3.1

–4.1 ± 3.7

0.144

   

 Plateau

–5.8 ± 4.7

–4.8 ± 3.5

0.182

   

Medial compartment

–6.3 ± 3.2

–8.1 ± 4.2

0.018

   

 Condyle

–5.5 ± 3.9

–7.7 ± 4.7

0.008

   

 Plateau

–7.6 ± 4.0

–8.6 ± 4.8

0.276

   

Synovial membrane thicknessb (mm)

0.13 ± 0.25

0.14 ± 0.24

0.948

   

Synovial fluid volume (ml)

–2.6 ± 14.5

–2.0 ± 11.8

0.776

   

BML scoreb

1.1 ± 1.7

0.8 ± 1.7

0.322

   

ATP population

12 months

24 months

Chondroitin sulfate

Celecoxib

p valuea

Chondroitin sulfate

Celecoxib

p valuea

(n = 57)c

(n = 63)

(n = 57)c

(n = 63)

Cartilage volume loss (%)

 Lateral compartment

–3.4 ± 2.7

–3.3 ± 2.5

0.932

–4.6 ± 3.0

–4.4 ± 2.8

0.753

  Condyle

–2.5 ± 3.2

–3.0 ± 3.0

0.234

–3.4 ± 3.0

–4.2 ± 3.6

0.316

  Plateau

–4.6 ± 3.5

–3.8 ± 3.1

0.194

–6.3 ± 4.6

–4.8 ± 3.5

0.081

 Medial compartment

–4.5 ± 2.6

–5.6 ± 3.0

0.049

–6.6 ± 3.3

–8.4 ± 4.2

0.021

  Condyle

–3.8 ± 3.2

–5.0 ± 3.8

0.100

–5.7 ± 4.0

–8.1 ± 4.7

0.010

  Plateau

–5.5 ± 3.0

–6.6 ± 3.8

0.155

–8.0 ± 4.2

–9.0 ± 4.8

0.334

Synovial membrane thicknessb (mm)

0.03 ± 0.18

0.06 ± 0.18

0.579

0.15 ± 0.26

0.15 ± 0.24

0.731

Synovial fluid volume (ml)

–5.5 ± 12.6

–1.8 ± 9.2

0.326

–3.9 ± 15.4

–2.1 ± 12.2

0.945

BML scoreb

0.7 ± 1.4

0.3 ± 1.2

0.051

1.1 ± 1.7

0.8 ± 1.7

0.322

  1. Data are mean ± standard deviation
  2. aAnalysis of covariance; model includes BMI as covariate; bold indicates statistical significance
  3. bGlobal knee
  4. cAmong the 58 patients in the chondroitin sulfate group who completed the study, one patient did not complete the MRI at 24 months
  5. ATP according-to-protocol, BMI body mass index, BML bone marrow lesion, LOCF last observation carried forward, mITT modified intention-to-treat, MRI magnetic resonance imaging